STAMPEDE Innovation Event
Hear about innovations and projects from across the prostate cancer community.
What was the event about?
This time, we explored the insights gained from the STAMPEDE trial and what it means for patients living longer with advanced prostate cancer. We heard from our fantastic expert speakers, Professor Noel Clarke and Dr Ashwin Sachdeva, and from our guest Steven Shaw who shared the patient perspective.
Interested in signing up to our next Innovation Event?
Don’t miss the chance to join our second Innovation Event of the year and hear from expert speakers on an important topic.
Meet the speakers
Professor Noel Clarke
Professor Noel Clarke is a Consultant Urological Surgeon and Clinician Scientist. He manages complex urological cancer surgery and plans and coordinates studies in urological cancer through basic/translational science and clinical trials. Surgically, he specialises in secondary and tertiary referral complex pelvic and retroperitoneal cancers, dealing with high volume complex urological malignancies and rare abdomino-pelvic tumours. In prostate cancer research and treatment he leads the GU research and FASTMAN prostate cancer research teams at The Christie / University of Manchester Cancer Research Institute, one of the largest prostate cancer research groups in the UK. In trials he is Co-PI of the STAMPEDE and RADICALS trials and jointly coordinates other international studies (Propel, Patch, IceCaP, StopCaP). He is the joint clinical lead for the National Prostate Cancer Audit (www.npca.org) in England and Wales. He has published over 295 peer reviewed scientific papers and co-authored 9 book chapters on urological cancer and its management.
Dr Ashwin Sachdeva
Dr Ashwin Sachdeva is a National Institute of Health and Care Research Academic Clinical Lecturer in Urology at the University of Manchester and The Christie Hospital. Ashwin has a special interest in translational prostate cancer research and has won the prestigious Prostate Cancer Foundation Young Investigator Award to support his innovative work linking trial data with imaging and routinely collected health data as part of the world-leading STAMPEDE trial. This work will investigate treatment toxicity in advanced prostate cancer and the potential approaches to minimise these side-effects.
Steven Shaw
Steven Shaw is a patient voice from Nottinghamshire and was a part of the STAMPEDE trial.
Do you have an exciting innovation or project to share?
If you'd like to share a project or innovation that you've led on, which has improved the prostate cancer pathway for men, please do get in touch.
We're interested in hearing about projects including (but not limited to):
- Prostate cancer risk awareness campaigns
- Diagnosing prostate cancer earlier, e.g., the faster diagnostic standard, optimal timed pathway for prostate cancer and rapid diagnostics
- Nurse-led triage
- Implementation of mpMRI and LATP biopsy
- Personalised care and supported self-management
